MVX tracks mortality across several cohorts, but nobody has shown that lowering the score improves survival, or what a healthy person should do with the result.
I have three Thorne products in my cabinet. Here is what the P&G Thorne acquisition actually changes, based on the brands bought before it.
When insurance says no, the drug costs what LillyDirect and NovoCare charge, just about wherever you buy it. The prescribing service is the part you can shop, and it runs from about $100 to nearly $1,700 a year.
A trademark, a Netflix series, and about $100,000 a year for a city to keep the certification. The business kept growing while the science underneath it kept shrinking.
ZEUS lowered inflammation exactly as designed and did not cut cardiovascular events. That weakens hs-CRP as something to treat, not as something worth measuring. In April I posted a Scientific American piece to r/ProactiveHealth headlined heart disease patients can be saved by drugs that calm inflammation. I hedged in the body. I wrote that “inflammation”
Oral semaglutide missed its primary endpoint for drinking. The VA’s new 622-person phase 3 is built on the one result that trial failed to get.
Both drugs block PCSK9 and cut LDL by about the same amount. Repatha is available now and cheap for most insured people. Lipfendra saves you the needle but asks for a daily fasting window, and its only published price is a list price.
The fight that decides what you will pay for the strongest obesity drug yet seen in large trials comes down to a single amino acid, and nobody has won it yet.
The FDA’s compounding committee voted on seven peptides, recommending BPC-157. What peptides are, why the market exploded, and what the vote does and does not decide.
My TRT clinic prescribed 5 mg of tadalafil a day. Here is what it is actually proven to do for the prostate and ED, what the podcasts oversell, and the one drug interaction to never ignore.
